Most people know that type 2 diabetes affects blood sugar. Fewer know that it can also weaken muscle over time. And fewer still realize the relationship may run both ways — that losing muscle can make diabetes harder to control, while diabetes can accelerate muscle loss. For many aging adults, this can become a slow, compounding cycle that unfolds quietly, long before disability is obvious.
Why Muscle Is a Metabolic Organ
Skeletal muscle is not simply what lets you lift things. It is one of the body’s primary metabolic engines — and the main tissue responsible for clearing glucose from the bloodstream in response to insulin. Under insulin-stimulated conditions, muscle accounts for roughly 80% of glucose disposal.¹ When muscle mass and muscle function decline, that capacity shrinks, and blood sugar regulation becomes harder. This is the foundation of a relationship researchers have been piecing together for years.
Evidence from Both Directions
Starting from the muscle side: low muscle mass predicts higher diabetes risk
Large observational studies suggest that adults with lower muscle mass — especially when muscle is low relative to body weight — have higher risk of developing type 2 diabetes later.
For example, in the Korean Genome and Epidemiology Study (KoGES), individuals with lower appendicular lean mass relative to body weight had roughly two-fold higher risk of developing type 2 diabetes compared with those in the highest muscle group, even after adjusting for confounders.² Risk appeared even higher when low muscle mass coincided with obesity.²
Important note: these data are observational. They do not prove that low muscle mass causes diabetes, but they strongly suggest muscle status is part of the risk profile.
Going the other direction: diabetes accelerates muscle loss and weakness
The reverse pattern also shows up repeatedly: type 2 diabetes is associated with faster muscle decline and greater weakness with aging.
In the Health ABC Study (over 2,600 older adults), women with type 2 diabetes experienced significantly greater losses in thigh muscle area over five years compared with non-diabetic controls.¹ In the Korean Sarcopenic Obesity Study, adults with diabetes had approximately threefold higher odds of having low skeletal muscle mass relative to body weight.¹
And in a clinic-based cross-sectional study from Brazil, sarcopenia prevalence was more than double in adults with diabetes compared to matched controls.³ Notably, the biggest difference between groups showed up in grip strength — suggesting that diabetes-related sarcopenia may sometimes present as weakness and impaired function even when muscle mass changes are less dramatic.³
How Diabetes Damages Muscle
Several biological pathways have been proposed — and are supported by mechanistic and observational evidence — to explain how diabetes may contribute to muscle loss and weakness.¹
1) Insulin resistance
Insulin normally supports muscle protein synthesis and repair. When tissues become insulin resistant, that anabolic signaling weakens, and the balance can shift toward breakdown. Some evidence suggests these changes can begin even before diabetes is fully established.¹
2) Chronic inflammation
Type 2 diabetes is associated with chronically elevated inflammatory markers, including interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha. In Health ABC, higher IL-6 levels were associated with lower grip strength — a functional marker closely tied to sarcopenia.¹
3) Oxidative stress and mitochondrial dysfunction
Diabetes increases oxidative stress, while aging reduces antioxidant defenses — a combination that can impair the satellite cells responsible for muscle repair and regeneration.¹
Mitochondrial dysfunction may be a key link. Small human studies report substantially reduced muscle mitochondrial capacity in people with type 2 diabetes compared with BMI-matched controls, and poorer glycemic control appears to correlate with worse mitochondrial function.¹
4) Complications that limit movement
Diabetes-related neuropathy and vascular disease can reduce mobility, increase fatigue, and impair muscle performance. Over time, reduced movement feeds back into muscle loss — and the cycle intensifies.¹
What This Actually Means for People
This is not just a lab-story.
Across clinical settings, low muscle mass is consistently associated with worse outcomes: higher mortality risk, longer hospital stays, higher complication rates, and poorer quality of life. A narrative review in Annals of Medicine summarizes this pattern across the continuum of care.⁴
And a meta-analysis across clinical conditions found that lower lean mass was associated with higher all-cause mortality overall (about a 37% higher risk per standard-deviation reduction in lean mass).⁵
Function is where the consequences become most visible. In a large national study of more than 13,000 Chinese adults aged 65 and older, lower muscle mass was associated with greater difficulty performing daily tasks — dressing, cooking, managing finances — and the relationship was strongest below sex-specific muscle thresholds.⁶
For someone living with diabetes, functional decline can become a feedback loop: less ability to move → harder blood sugar control → faster muscle loss → further functional decline.
Can the Cycle Be Broken?
The most consistently supported lever is physical activity, especially resistance training.
Exercise improves insulin sensitivity, preserves or increases muscle strength, and can blunt muscle loss during aging. A network meta-analysis suggests that combining resistance and aerobic exercise produces the most meaningful improvements in long-term glycemic control (HbA1c) compared with either alone.¹
Resistance training is especially relevant because it directly targets what diabetes and aging erode: strength and muscle quality. It also helps preserve lean mass during weight loss — an important consideration, since caloric restriction used to manage diabetes can reduce muscle mass alongside fat if protein and resistance exercise are not prioritized.¹⁴
What the Evidence Does Not Yet Settle
Many studies in this area are cross-sectional, capturing a snapshot rather than tracking people over time. This makes it difficult to confirm causality — whether muscle loss leads to diabetes, diabetes leads to muscle loss, or both happen simultaneously from shared underlying causes.
There is also no universally agreed-upon definition of sarcopenia, which complicates comparisons across studies. And most intervention trials have not specifically targeted people with both conditions at once. What the optimal treatment strategy looks like for that combined population remains an open question.
The Plain-Language Takeaway
Muscle is a metabolic organ, and keeping it healthy matters — especially as we age and especially for those managing type 2 diabetes. The research makes a compelling case that sarcopenia and type 2 diabetes form a self-reinforcing cycle, each creating biological conditions that make the other worse. Regular physical activity, adequate protein intake, and careful metabolic management offer real, evidence-based ways to break into that cycle.
This does not mean everyone with diabetes will develop sarcopenia, or vice versa. But it does mean that muscle health deserves far more attention in how we think about — and treat — metabolic disease.
Strength of evidence
Moderate to Strong
Multiple large observational studies and consistent mechanistic evidence support the bidirectional relationship. However, causality is difficult to confirm from observational data alone, sarcopenia definitions remain inconsistent across studies, and intervention trials specifically targeting people with both conditions are still limited.
References
-
Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019;12:1057–1072. doi:10.2147/DMSO.S186600
-
Son JW, Lee SS, Kim SR, et al. Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. Diabetologia. 2017;60(5):865–872. doi:10.1007/s00125-016-4196-9
-
Pechmann LM, Jonasson TH, Canossa VS, et al. Sarcopenia in type 2 diabetes mellitus: a cross-sectional observational study. Int J Endocrinol. 2020;2020:7841390. doi:10.1155/2020/7841390
-
Prado CM, Purcell SA, Alish C, et al. Implications of low muscle mass across the continuum of care: a narrative review. Ann Med. 2018;50(8):675–693. doi:10.1080/07853890.2018.1511918
-
Lee GKY, Au PCM, Li GHY, et al. Sarcopenia and mortality in different clinical conditions: A meta-analysis. Osteoporos Sarcopenia. 2021;7(Suppl 1):S19–S27. doi:10.1016/j.afos.2021.02.001
-
Chen L, Lu Y, Zhu P. Association between appendicular skeletal muscle mass index and daily living activities in Chinese elderly: a cross-sectional study based on CLHLS 2018. Front Public Health. 2025;13:1645850. doi:10.3389/fpubh.2025.1645850
